ライフサイエンスコーパス: proton pump inhibitor

1 cidifying the cytosol with bafilomycin A1, a proton pump inhibitor.

2 Testing was performed on maintenance proton pump inhibitor.

3 re, with four (21%) of 19 patients needing a proton-pump inhibitor.

4 that esophageal eosinophilia can respond to proton pump inhibitors.

5 asibility before and after administration of proton pump inhibitors.

6 long-term history of diarrhea, responsive to proton pump inhibitors.

7 tions were similar when we excluded users of proton pump inhibitors.

8 but the survival benefit of 0.0167% favored proton pump inhibitors.

9 crine tumors, is elevated in patients taking proton pump inhibitors.

10 ed VHs that were induced or enhanced by oral proton pump inhibitors.

11 Medical management of GERD mainly uses proton pump inhibitors.

12 C. difficile-associated diarrhea with use of proton pump inhibitors.

13 patients requiring maintenance therapy with proton pump inhibitors.

14 opy and esophageal pH monitoring, and use of proton pump inhibitors.

15 onomic problem, due to the widespread use of proton pump inhibitors.

16 hese patients were successfully treated with proton-pump inhibitors.

17 neric-equivalent beta-blockers, statins, and proton-pump inhibitors.

18 essed at baseline while they were not taking proton-pump inhibitors.

19 and reminders to reduce inappropriate use of proton-pump inhibitors.

20 ntestinal bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limita

21 Results for proton-pump inhibitors (2.1 percentage points [CI, -3.7

22 tigation include substituting vonoprazan for proton pump inhibitors, adding probiotics, and vaccine d

23 High dose intravenous proton pump inhibitor after endoscopic therapy for pepti

24 he clinical efficacy of oral and intravenous proton pump inhibitor after endoscopic therapy.

25 d received either 10-day sequential therapy (Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days a

26 sociated diarrhea, although judicious use of proton pump inhibitors and antibiotics, emphasis on hand

27 (27%-66%) reduction for concurrent users of proton pump inhibitors and coxibs.

28 nocarcinoma coincided with popularization of proton pump inhibitors and has focused attention on gast

29 phylaxis, review the comparative efficacy of proton pump inhibitors and histamine 2 receptor antagoni

30 There were no differences between proton pump inhibitors and histamine 2 receptor antagoni

31 olone use; there is also an association with proton pump inhibitors and increased recognition of case

32 BACKGROUND& AIMS: Proton pump inhibitors and nonsteroidal anti-inflammator

33 MI patterns before and after treatment with proton pump inhibitors and to compare the performance of

34 Using full-dose proton-pump inhibitor and high-dose Metronidazole in gro

35 Using full-dose proton-pump inhibitor and higher doses of Metronidazole

36 dose Metronidazole in group A, and full-dose proton-pump inhibitor and prescription from a Gastroente

37 parietal cell proton pump and development of proton pump inhibitors, and (3) identification of Helico

38 , change in body mass index, smoking, use of proton pump inhibitors, and anti-diabetic medications, a

39 Lifestyle modifications, proton pump inhibitors, and laparoscopic fundoplication

40 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, and Nissen fundoplication.

41 By contrast, patient age, the use of proton pump inhibitors, and the use of primary prophylax

42 idemic agents, antidepressants, prescription proton-pump inhibitors, and muscle relaxants.

43 py and 8 weeks of maintenance therapy with a proton pump inhibitor; and 4) patients receiving follow-

44 nce interval (CI): 2.1, 5.0), current use of proton pump-inhibitor antiheartburn medications (OR = 6.

45 r histamine 2 receptor antagonists; however, proton pump inhibitors appear to be the dominant drug cl

46 Whether proton pump inhibitors are more effective than histamine

47 Although studies implicate proton pump inhibitors as a risk for CDI, the magnitude

48 50% treatment-experienced, and 30% receiving proton pump inhibitors at start of treatment.

49 and a 50% or greater reduction in the use of proton-pump inhibitors at 1 year.

50 impact on phagosome permeabilization of the proton pump inhibitor bafilomycin A.

51 n effect that was inhibited by the lysosomal proton pump inhibitor, bafilomycin A1.

52 Standard proton-pump inhibitor-based therapy for Helicobacter pyl

53 ibitor, the micromotors can function without proton pump inhibitors because of their built-in proton

54 of peptic ulcer without co-prescription of a proton-pump inhibitor; beta blockers prescribed to those

55 Whether oral proton pump inhibitor can replace intravenous proton pum

56 f lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based

57 hibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronid

58 Proton pump inhibitors, commonly used for gastric acid s

59 reased, reflux symptoms improved, and use of proton-pump inhibitors decreased.

60 Proton pump inhibitors defend the mucosa from injury by

61 interactions with H2-receptor antagonists or proton pump inhibitors, does not cause central nervous s

62 udies, between high-dose or long-term use of proton pump inhibitor drugs and certain possibly attribu

63 Therapies include proton pump inhibitors, elimination diets, and topical c

64 The adjusted odds ratio for > or =5 years of proton pump inhibitor exposure was 1.1 (95% confidence i

65 Histamine receptor-2 antagonist or proton pump inhibitor for 9 days of stress ulcer prophyl

66 Concurrent users of NSAIDs and proton pump inhibitors had a 54% (27%-72%) risk reductio

67 The pharmacodynamic efficacy of proton pump inhibitors has not been specifically evaluat

68 eatment using tetracycline, furazolidone and proton-pump inhibitors has been effective and low cost i

69 Patients receiving oral proton pump inhibitor have a shorter hospital stay.

70 Statins and proton pump inhibitors have been shown to decrease adver

71 While proton pump inhibitors have been widely used for blockin

72 e macular degeneration patients treated with proton pump inhibitors having the core structure, 2-pyri

73 apies with evidence of effectiveness include proton pump inhibitors, histamine-2 receptor antagonists

74 eoxycholic acid, and the addition of an oral proton-pump inhibitor improved weight gain and survival.

75 , but it is not known whether treatment with proton pump inhibitors improves asthma control.

76 roton pump inhibitor can replace intravenous proton pump inhibitor in this setting is unknown.

77 ating the efficacy and safety of withholding proton pump inhibitors in critically ill patients.

78 here is very low certainty for the effect of proton pump inhibitors in patients with esophageal eosin

79 les of several commercial controlled-release proton pump inhibitors in simulated stomach and intestin

80 Empiric trial using proton pump inhibitors is still the recommended initial

81 therefore coadministration of aspirin with a proton-pump inhibitor is an attractive option and is und

82 to tailor therapy, but an empiric trial of a proton pump inhibitor may be an alternative diagnostic a

83 t that dipeptidyl peptidase-4 inhibitors and proton-pump inhibitors might enhance beta-cell survival

84 antibiotics, opioid analgesics, adrenergics, proton-pump inhibitors, nitroglycerin, diazepam, metoclo

85 es, a reduction of 50% or more in the use of proton-pump inhibitors occurred in 93% of patients, and

86 eflux disease who have a partial response to proton-pump inhibitors often seek alternative therapy.

87 This cleavage was blocked by the proton pump inhibitor omeprazole and mediated by the aci

88 Administration of the proton pump inhibitor omeprazole can reduce both esophag

89 The proton pump inhibitor omeprazole is administered to dogs

90 in complex with a human drug substrate, the proton pump inhibitor omeprazole.

91 Strikingly, the proton-pump inhibitor omeprazole similarly altered the m

92 per gastrointestinal bleeding; the effect of proton pump inhibitors on ventilator-associated pneumoni

93 ts of lansoprazole (LANZO) administration, a proton pump inhibitor, on the dystrophic muscle phenotyp

94 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, open fundoplication, and laparos

95 s) are use of a coxib or concurrent use of a proton pump inhibitor or double-dose histamine-2 recepto

96 dication was defined as a combination use of proton pump inhibitor or H2 receptor blockers, plus clar

97 ally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonis

98 ux, defined as use of antireflux medication (proton pump inhibitors or histamine2 receptor antagonist

99 of the three trials, 124 (51%) were taking a proton-pump inhibitor or H2 blocker at enrolment.

100 edication use was defined as any order for a proton-pump inhibitor or histamine(2) receptor antagonis

101 use was defined as any pharmacy charge for a proton-pump inhibitor or histamine-2 receptor antagonist

102 p) in patients who were and were not using a proton-pump inhibitor or histamine-receptor-2 (H2) block

103 ndamycin (odds ratio [OR]: 1.23, P = .01) or proton pump inhibitors (OR: 1.20, P < .001) in the 90 da

104 The association was significant for proton-pump inhibitors (OR = 2.7, 95% CI = 1.4-5.4), but

105 The association was significant for proton-pump inhibitors (OR, 1.3; 95% CI, 1.1-1.4) but no

106 ot clearly support lower bleeding rates with proton pump inhibitors over histamine 2 receptor antagon

107 r initial response to any therapy, including proton pump inhibitors (P < .001).

108 gests that standard three-drug regimens of a proton-pump inhibitor plus amoxicillin and clarithromyci

109 ion regarding the safety of co-prescribing a proton pump inhibitor (PPI) and clopidogrel.

110 (OR 2.43(2.06-2.88) and 1.90 (1.68-2.14) for proton pump inhibitor (PPI) and histamine 2 receptor ant

111 Outcome in proton pump inhibitor (PPI) and non-PPI users was classi

112 with esophageal disease, but the effects of proton pump inhibitor (PPI) drugs are incompletely chara

113 Observational studies linking proton pump inhibitor (PPI) exposure with community-acqu

114 t in vitro and animal studies have found the proton pump inhibitor (PPI) lansoprazole to be highly ac

115 esponse (SVR) included age, race, cirrhosis, proton pump inhibitor (PPI) prescription, prior HCV trea

116 Esophageal eosinophilia can be proton pump inhibitor (PPI) resistant or responsive, rep

117 ficance and plausible mechanisms underlying 'proton pump inhibitor (PPI) responsive oesophageal eosin

118 ageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy (partial responders)

119 RD) commonly starts with an empiric trial of proton pump inhibitor (PPI) therapy and complementary li

120 any patients have only a partial response to proton pump inhibitor (PPI) therapy and continue to expe

121 Proton pump inhibitor (PPI) therapy fails to provide ade

122 Inadequate response to proton pump inhibitor (PPI) therapy in patients with gas

123 Intravenous bolus plus infusion proton pump inhibitor (PPI) therapy is recommended for p

124 This study assessed the effect of proton pump inhibitor (PPI) therapy on the volume, distr

125 Partial response to proton pump inhibitor (PPI) therapy poses a healthcare c

126 mfort persists despite maximal (double-dose) proton pump inhibitor (PPI) therapy taken appropriately

127 Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fr

128 Demographics, duration of symptoms and proton pump inhibitor (PPI) therapy, GERD-Health Related

129 some patients whose symptoms persist despite proton pump inhibitor (PPI) therapy.

130 referral of TS, in patients without previous proton pump inhibitor (PPI) treatment and in patients on

131 present in BE patients are reversible after proton pump inhibitor (PPI) treatment.

132 4.61; 95% CI, 1.42 to 15.0; P = 0.011), and proton pump inhibitor (PPI) use (OR, 3.50; 95% CI, 1.19

133 : Studies have reported associations between proton pump inhibitor (PPI) use and dementia.

134 were hospitalized and they had higher MELD, proton pump inhibitor (PPI) use and HE without differenc

135 0.13), perioperative outcome, regurgitation, proton pump inhibitor (PPI) use, lower esophageal sphinc

136 On the second day of investigation, proton pump inhibitor (PPI) was given at a mean dose of

137 GERD patients who were being treated with a proton pump inhibitor (PPI), 50% had pathologic esophage

138 k course eradication therapy consisting of a proton pump inhibitor (PPI), amoxicillin, and clarithrom

139 When erlotinib is taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, which

140 the value of skin tests in the diagnosis of proton pump inhibitor (PPI)-induced hypersensitivity rea

141 Between 1997 and 1999, 177 patients with proton pump inhibitor (PPI)-refractory GERD were randomi

142 igation is required in the assessment of the proton pump inhibitor (PPI)-refractory patient.

143 tidyl peptidase IV inhibitor (DPP-4i), and a proton pump inhibitor (PPI).

144 symptoms can be medicated empirically with a proton pump inhibitor (PPI).

145 BACKGROUND & AIMS: Proton pump inhibitors (PPI) are among the top 10 most p

146 Proton pump inhibitors (PPI) are an invaluable therapy o

147 BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with a

148 armacokinetic studies have demonstrated that proton pump inhibitors (PPI) reduce exposure of mycophen

149 temic treatment of B16-OVA-bearing mice with proton pump inhibitors (PPI) significantly increased the

150 The association between proton pump inhibitors (PPI) use and risk of acute inter

151 (NMA) was conducted to compare the different proton pump inhibitors (PPI) within triple therapy.

152 ion using standard triple therapy (STT) with proton pump inhibitors (PPI), amoxicillin and clarithrom

153 Limited evidence suggests that proton pump inhibitors (PPI), nonsteroidal anti-inflamma

154 cessful endoscopic therapy receive high-dose proton-pump inhibitor (PPI) therapy (intravenous loading

155 omes in partial responders to high-dose (HD) proton-pump inhibitor (PPI) therapy and to evaluate dura

156 nic hepatitis C virus (HCV) are on prolonged proton-pump inhibitor (PPI) therapy and wish to remain o

157 Heartburn that persists despite proton-pump inhibitor (PPI) treatment is a frequent clin

158 ds ratios (ORs) were calculated for GORD and proton-pump inhibitor (PPI) use in hormone and non-hormo

159 ority of children with EoE not responsive to proton-pump inhibitor (PPI), inflammation is driven by s

160 Many studies have shown that high-dose proton-pumps inhibitors (PPI) do not further reduce the

161 de concomitant nonbismuth quadruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazol

162 ons have been demonstrated with misoprostol, proton pump inhibitors (PPIs) (only documented in high-r

163 n open-label crossover trial to test whether proton pump inhibitors (PPIs) affect the gastrointestina

164 20 under medical treatment with 40 mg/day of proton pump inhibitors (PPIs) and 25 after Nissen fundop

165 eported on the effects of concomitant use of proton pump inhibitors (PPIs) and dual antiplatelet ther

166 Proton pump inhibitors (PPIs) and histamine 2 receptor a

167 Proton pump inhibitors (PPIs) and histamine-2 receptor a

168 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) and histamine-2 receptor a

169 The association between proton pump inhibitors (PPIs) and nontyphoid salmonellos

170 Proton pump inhibitors (PPIs) are among the most common

171 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are commonly used medicati

172 Proton pump inhibitors (PPIs) are frequently used after

173 Proton pump inhibitors (PPIs) are gastric acid-suppressi

174 Proton pump inhibitors (PPIs) are popular drugs for gast

175 Proton pump inhibitors (PPIs) are used for the long-term

176 Proton pump inhibitors (PPIs) are widely used for the tr

177 Proton pump inhibitors (PPIs) are widely used to treat g

178 an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of

179 reflux esophagitis successfully treated with proton pump inhibitors (PPIs) began 24-hour esophageal p

180 Proton pump inhibitors (PPIs) can contribute to small-bo

181 have hypothesized that the long-term use of proton pump inhibitors (PPIs) can increase the risk of d

182 ed RR of UGIB associated with current use of proton pump inhibitors (PPIs) for more than 1 month was

183 lux disease (GERD) who are not responding to proton pump inhibitors (PPIs) given once daily are very

184 Use of proton pump inhibitors (PPIs) has been associated with e

185 Proton pump inhibitors (PPIs) have been known to induce

186 Proton pump inhibitors (PPIs) have been recognized as a

187 Safety issues associated with proton pump inhibitors (PPIs) have recently attracted wi

188 Certain proton pump inhibitors (PPIs) interfere with clopidogrel

189 Proton pump inhibitors (PPIs) may be a risk factor for h

190 Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for

191 Proton pump inhibitors (PPIs) might reduce the risk of s

192 study was to assess the effects of different proton pump inhibitors (PPIs) on the steady-state pharma

193 dyspepsia (FD), the effect and mechanism of proton pump inhibitors (PPIs) or first-line therapy rema

194 was use of acid suppression medication with proton pump inhibitors (PPIs) or histamine-2 receptor an

195 res (controls), prescription data for use of proton pump inhibitors (PPIs) or histamine-2 receptor an

196 Proton pump inhibitors (PPIs) or histamine-2 receptor bl

197 omes in patients who were taking concomitant proton pump inhibitors (PPIs) or low-dose aspirin.

198 Proton pump inhibitors (PPIs) predispose to bacterial ov

199 ncreasing incidence of chronic liver disease.Proton pump inhibitors (PPIs) reduce gastric acid secret

200 Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebo

201 e of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear.

202 of patients with GERD who receive label-dose proton pump inhibitors (PPIs) still have symptoms.

203 Adding proton pump inhibitors (PPIs) to endoscopic therapy has

204 extraesophageal reflux are often prescribed proton pump inhibitors (PPIs) to reduce gastric acid ass

205 ross-sectional study, 8.5% of patients using proton pump inhibitors (PPIs) were rectal carriers of ex

206 monary disease (COPD), ulcer history, use of proton pump inhibitors (PPIs), aspirin, nonsteroidal ant

207 y of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may hav

208 e the risks associated with long-term use of proton pump inhibitors (PPIs), focusing on long-term use

209 Proton pump inhibitors (PPIs), frequently prescribed to

210 view summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional def

211 cid-reducing agents, such as H2 blockers and proton pump inhibitors (PPIs), remains a controversial r

212 Proton pump inhibitors (PPIs), which are commonly used a

213 f this association is modulated by intake of proton pump inhibitors (PPIs).

214 s with IPF placed on antacid therapy such as proton pump inhibitors (PPIs).

215 and persistent GERD symptoms despite use of proton pump inhibitors (PPIs).

216 etween the available antiplatelet agents and proton pump inhibitors (PPIs).

217 2.6, 95% confidence interval [CI] 1.5-4.7), proton pump inhibitors (PPIs; OR 2.1, 95% CI 1.3-3.4), a

218 Proton-pump inhibitors (PPIs) and clopidogrel are freque

219 Proton-pump inhibitors (PPIs) are believed to decrease t

220 Proton-pump inhibitors (PPIs) are often prescribed in co

221 Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for

222 Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointest

223 f Gastrointestinal Events Trial) showed that proton-pump inhibitors (PPIs) safely reduced rates of ga

224 Proton pump inhibitors, PPIs, are widely prescribed and

225 Proton-pump inhibitors, PPIs, are considered effective t

226 Here, we show that proton pump inhibitors promote progression of alcoholic

227 Patients (18-50 years) with proton pump inhibitor-resistant esophageal eosinophilia

228 causes of esophageal eosinophilia, including proton-pump inhibitor responsive esophageal eosinophilia

229 role of gastroesophageal reflux disease and proton pump inhibitor-responsive esophageal eosinophilia

230 causes of esophageal eosinophilia, including proton pump inhibitor-responsive esophageal eosinophilia

231 Proton-pump inhibitor-responsive esophageal eosinophilia

232 tamine receptor-2 antagonist and $7,802 with proton pump inhibitor, resulting in a cost saving of $1,

233 In critically ill patients, proton pump inhibitors seem to be more effective than hi

234 itis and allergies, twice-daily therapy with proton pump inhibitors significantly improved symptoms a

235 Proton pump inhibitor single therapy did not significant

236 g methods, enhancing antibiotic and possibly proton pump inhibitor stewardship, and prescribing proph

237 Two proton pump inhibitors, tenatoprazole and esomeprazole,

238 The proton pump inhibitor test has been formally described a

239 the intralysosomal pH, since ionophores and proton pump inhibitors that dissipate the lysosomal pH g

240 that were either treated with omeprazole, a proton-pump inhibitor that suppresses acid secretion in

241 duction, or pharmacologically treated with a proton pump inhibitor, the ability of pGP3-deficient C.

242 cy as the positive control of free drug plus proton pump inhibitor, the micromotors can function with

243 group and 31% of the control group chose the proton-pump inhibitor, the superior drug (P < 0.001).

244 The relationship between proton pump inhibitor therapy and other acid suppressing

245 agement considerations (potential indefinite proton pump inhibitor therapy and/or surveillance endosc

246 Long-term proton pump inhibitor therapy at a regular dose is not a

247 tly weakly acidic reflux despite twice-daily proton pump inhibitor therapy before RFA increases the i

248 Chronic acid suppression by proton pump inhibitor therapy can lead to hypergastrinem

249 vement in GERD symptoms, quality of life and proton pump inhibitor therapy elimination after radiofre

250 rch Datalink was additionally used to assess proton pump inhibitor therapy for at least 6 months (med

251 ce costs with survival benefit comparable to proton pump inhibitor therapy for stress ulcer prophylax

252 -based triple and high-dose dual amoxicillin proton pump inhibitor therapy for subsequent treatment a

253 We investigated whether proton pump inhibitor therapy improved symptoms in patie

254 vironment created by surgical gastrectomy or proton pump inhibitor therapy in combination with a high

255 ibiotics are effective; notably, intravenous proton pump inhibitor therapy in lieu of vasoconstrictor

256 imal acid suppression (twice daily dosing of proton pump inhibitor therapy) in 8-12 weeks.

257 urgical reintervention and 1192 (59.5%) used proton pump inhibitor therapy, with risk factors for the

258 GERD therapy are a promising alternative to proton pump inhibitor therapy.

259 ase and this can be effectively treated with proton pump inhibitor therapy.

260 of interest was > or =5 years of cumulative proton pump inhibitor therapy.

261 Proton-pump inhibitor therapy started within the past 30

262 rosive esophagitis after a 2-month course of proton-pump inhibitor therapy to assess healing and rule

263 apeutic trial of 4 to 8 weeks of twice-daily proton-pump inhibitor therapy.

264 Among patients who used proton pump inhibitors, there was no significant associa

265 Proton pump inhibitors, thyroid hormones, and dihydropyr

266 Further data integration links proton pump inhibitors to circulating metabolites, liver

267 d controlled parallel group trials comparing proton pump inhibitors to histamine 2 receptor antagonis

268 osal eosinophil count, age, sex, and current proton pump inhibitor treatment did not predict this lim

269 (Use of high dose proton pump inhibitor treatment or normal pH monitoring)

270 et agents, had a medical condition requiring proton pump inhibitor treatment, or had already received

271 24-hour impedance-pH testing; they received proton pump inhibitors twice daily.

272 A retrospective cohort of proton-pump inhibitor-unresponsive, non-glucocorticoid-t

273 tburn (mean score 3.2 vs 1.4, p = 0.001) and proton pump inhibitor use (41.7% vs 17.1%, p = 0.023) we

274 cular disease (HR, 1.95; 95% CI, 1.14-3.33), proton pump inhibitor use (HR, 1.87; 95% CI, 1.54-2.27),

275 additional recommendations by the panel were proton pump inhibitor use as a risk factor and the use o

276 Proton pump inhibitor use increases the risk of developi

277 rectal cancer, we examined whether long-term proton pump inhibitor use is associated with an increase

278 Modification of proton pump inhibitor use may increase rates of SVR.

279 Proton pump inhibitor use was associated with higher pla

280 Manometric changes, pH testing, and proton pump inhibitor use were assessed preoperatively a

281 tinal bleeding and a possible association of proton pump inhibitor use with Clostridium difficile and

282 ores, quality of life metrics, and change in proton pump inhibitor use) and objective metrics (pH par

283 Lower baseline eGFR, proton pump inhibitor use, and combination immune checkp

284 included Model for End-Stage Liver Disease, proton pump inhibitor use, and lower length of stay (c-s

285 g/dL), absence of cirrhosis, and absence of proton pump inhibitor use.

286 on exists between C. difficile infection and proton pump inhibitor use.

287 orted in the pediatric age range linked with proton pump inhibitor use.

288 y significant risk was demonstrated only for proton-pump inhibitor use.

289 Omeprazole is a proton pump inhibitor used in the treatment of peptic ul

290 Among high-dose proton pump inhibitor users (ie, > or =1.5 defined daily

291 meta-analyzed five trials (604 patients) of proton pump inhibitors versus placebo; there was no stat

292 tegy of stress ulcer prophylaxis with use of proton pump inhibitors vs histamine-2 receptor blockers

293 Exposure to proton pump inhibitors was found in 53% of cases (47% in

294 Proton pump inhibitors were more effective than histamin

295 H2RAs compared with proton pump inhibitors were not significantly different

296 treated with intravenous corticosteroids and proton pump inhibitors were randomly assigned to one 30-

297 Proton pump inhibitors were stopped at least 7 days befo

298 No proton-pump inhibitors were administered during follow-u

299 ephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the QT interval.

300 These findings suggest that coprescribing a proton pump inhibitor with an NSAID is as effective as u